SCHEMBL3398586

SCHEMBL3398586

Cc1ccc(CN)cc1Br.Cc1ccc(CN)cc1Br

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.39
HPGD P15428 2/20 0.38
LOXL2 Q9Y4K0 3/20 0.37
ALDH1A1 P00352 2/20 0.37
ABAT P80404 1/20 0.36
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
PNMT P11086 1/20 0.35
ENPP2 Q13822 1/20 0.35
CA12 O43570 1/20 0.35
CA4 P22748 1/20 0.35
CA6 P23280 1/20 0.35
CA5A P35218 1/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35
CA14 Q9ULX7 1/20 0.35
CA5B Q9Y2D0 1/20 0.35
ST14 Q9Y5Y6 1/20 0.35
CYP2A6 P11509 1/20 0.35
CSNK2A1 P68400 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1363463 1.00 HRH3 (0.39) HRH3HPGDLOXL2ALDH1A1ABAT
Hydrochloric Acid SCHEMBL3412254 0.98 MAPT (0.38) HRH3HPGDLOXL2ALDH1A1ABAT
SCHEMBL6915886 0.83 TAAR1 (0.50) ALDH1A1PNMTCYP2A6MAPTGAA
SCHEMBL967725 0.82 CSNK2A1 (0.39) HRH3LOXL2ALDH1A1ABATCA1
SCHEMBL17704659 0.81 ESR1 (0.48) HPGDALDH1A1CA1CA2CA4
Hydrochloric Acid SCHEMBL6773779 0.80 CSNK2A1 (0.41) HRH3LOXL2ALDH1A1ABATCA1
SCHEMBL10257025 0.79 HPGD (0.43) HPGDALDH1A1CA2CYP2A6MAPT
SCHEMBL1774615 0.79 HPGD (0.39) HPGDALDH1A1MAPTGAA
SCHEMBL29783216 0.79 HPGD (0.39) HPGDALDH1A1MAPTGAA
SCHEMBL39710 0.78 ALDH1A1 (0.46) HRH3LOXL2ALDH1A1ABATPNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8071588-B2 Dual pharmacophores—PDE4-muscarinic antagonistics GLAXO GROUP LIMITED (GB) 2011-12-06 US disclosed
EP-2247184-A1 DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS Glaxo Group Limited (GB) 2010-11-10 EP disclosed
US-20090203677-A1 Dual Pharmacophores - PDE4-Muscarinic Antagonistics GLAXO GROUP LIMITED (GB) 2009-08-13 US disclosed
WO-2009100167-A1 DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS GLAXO GROUP LIMITED (GB) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203677-A1 Dual Pharmacophores - PDE4-Muscarinic Antagonistics PDE4A, PDE4B, PDE1A HRH3 83/4885HPGD 370/4885LOXL2 1350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.